Table 1.
Clinicopathological characteristics and tumor expression of KIF20A in epithelial ovarian cancer
| Characteristic | Cases, n (%) |
|---|---|
| Age (years) | |
| ≤53 | 81 (54.0) |
| >53 | 69 (46.0) |
| FIGO stage | |
| I | 25 (18.5) |
| II | 18 (13.3) |
| III | 83 (61.5) |
| IV | 9 (6.7) |
| Histological type | |
| Serous adenocarcinoma | 119 (80.4) |
| Mucoid adenocarcinoma | 24 (16.2) |
| Endometrial adenocarcinoma | 3 (2.0) |
| Clear cell carcinoma | 2 (1.4) |
| Lymph node metastasis | |
| Absent | 71 (56.3) |
| Present | 55 (43.7) |
| Intraperitoneal metastasis | |
| No | 56 (37.3) |
| Yes | 94 (62.7) |
| Intestinal metastasis | |
| No | 68 (48.9) |
| Yes | 71 (51.1) |
| KIF20A expression | |
| Low or none | 60 (40.0) |
| High | 90 (60.0) |
| Vital status at last follow-up | |
| Alive | 69 (46.0) |
| Dead | 81 (54.0) |
| Tumor recurrence | |
| No | 60 (40.3) |
| Yes | 89 (59.7) |
| Intraperitoneal recurrence | |
| No | 69 (69.7) |
| Yes | 30 (30.3) |
| Distant recurrence | |
| No | 35 (60.3) |
| Yes | 23 (39.7) |
| Residual tumor size (cm) | |
| ≤1 | 98 (76.0) |
| >1 | 31 (24.0) |
| Differentiation grade | |
| G1/G2 | 64 (50.8) |
| G3 | 62 (49.2) |
| Neoadjuvant chemotherapy | |
| No | 113 (75.3) |
| Yes | 37 (24.7) |
| Postoperative chemotherapy | |
| No | 7 (4.7) |
| Yes | 143 (95.3) |
| HIPEC | |
| No | 108 (78.3) |
| Yes | 30 (21.7) |
| Ascites with tumor cells | |
| No | 44 (44.9) |
| Yes | 54 (55.1) |
| Cytoreductive surgery | |
| No | 26 (17.3) |
| Yes | 124 (82.7) |
| Drug resistance | |
| No | 30 (52.6) |
| Yes | 27 (47.4) |
| CA125 (U/mL) | |
| ≤35 | 7 (5.2) |
| >35 | 127 (94.8) |
| CA199 (U/mL) | |
| ≤35 | 93 (69.4) |
| >35 | 41 (30.6) |
| CA153 (U/mL) | |
| ≤25 | 27 (22.9) |
| >25 | 91 (77.1) |
| NSE (U/mL) | |
| ≤15.2 | 31 (36.9) |
| >15.2 | 53 (63.1) |
| CEA (U/mL) | |
| ≤5.0 | 90 (79.6) |
| >5.0 | 23 (20.4) |
| β-HCG (U/mL) | |
| ≤3.0 | 54 (80.6) |
| >3.0 | 13 (19.4) |
Abbreviations: β-HCG, β human choriogonadotropin; CEA, carcinoembryonic antigen; FIGO, International Federation of Gynecology and Obstetrics stage; HIPEC, hyperthermic intraperitoneal chemotherapy; NSE, neuron-specific enolase.